GlassScriptPhysician profile
Melissa E Krzus
NPI 1205243524
$6,128.95
in general payments reported to CMS, 2019-2025
51 companies · $1,094 in 2025
The $1,094 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $958 · 2022: $1,272 · 2023: $1,099 · 2024: $1,706 · 2025: $1,094.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,019 · Long Term Medical Supply Or Device Loan: $781 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,018.74 |
| Long Term Medical Supply Or Device Loan | $781.23 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,215.84 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $337.54 | 2021-2024 | Lynparza, Enhertu |
| Amgen INC. | $284.68 | 2021-2023 | Lumakras, Kyprolis |
| Merck Sharp & Dohme LLC | $256.04 | 2021-2025 | Keytruda, Welireg, Keytruda Qlex |
| Regeneron Healthcare Solutions, INC. | $236.69 | 2022-2024 | Libtayo |
| Astellas Pharma US INC | $231.88 | 2021-2025 | Padcev, Xtandi, Vyloy |
| Seagen INC. | $225.21 | 2022-2024 | Padcev |
| Pfizer INC. | $209.37 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $191.13 | 2022-2025 | Opdivo |
| Abbvie INC. | $186.29 | 2022-2025 | |
| Beigene USA, INC. | $164.26 | 2021-2024 | Brukinsa |
| Incyte Corporation | $157.74 | 2021-2025 | Monjuvi, Zynyz |
| Janssen Scientific Affairs, LLC | $147.06 | 2024 | Carvykti, Darzalex, Tecvayli |
| Sirtex Medical INC | $145.70 | 2022 | |
| Daiichi Sankyo INC. | $144.10 | 2021-2025 | Datroway, Enhertu |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $143.77 | 2021-2025 | Reblozyl |
| Puma Biotechnology, INC. | $141.34 | 2021-2024 | |
| Gilead Sciences, INC. | $124.52 | 2021-2024 | Trodelvy |
| Eisai INC. | $120.44 | 2021-2025 | |
| Stryker Corporation | $102.27 | 2025 | Augment Injectable |
| Rigel Pharmaceuticals, INC. | $101.43 | 2021-2024 | Rezlidhia, Tavalisse |
| Exelixis INC. | $101.17 | 2024-2025 | Cabometyx |
| Genzyme Corporation | $100.29 | 2021-2025 | |
| Janssen Biotech, INC. | $76.93 | 2022-2025 | Rybrevant |
| Takeda Pharmaceuticals U.S.A., INC. | $64.61 | 2022-2025 | Iclusig |
| Karyopharm Therapeutics INC. | $63.80 | 2021-2023 | Xpovio |
| Genentech USA, INC. | $61.97 | 2023-2025 | Tecentriq Hybreza, Venclexta, Polivy |
| Alexion Pharmaceuticals, INC. | $61.22 | 2021-2023 | Ultomiris |
| Glaxosmithkline, LLC. | $59.42 | 2024-2025 | Ojjaara, Zejula, Jemperli |
| Lilly USA, LLC | $58.82 | 2023-2025 | Jaypirca, Verzenio, Retevmo |
| Deciphera Pharmaceuticals INC. | $58.02 | 2021-2025 | Romvimza, Qinlock |
| Pharmacyclics LLC, An Abbvie Company | $56.36 | 2021-2023 | Epkinly, Imbruvica |
| Jazz Pharmaceuticals INC. | $53.92 | 2021-2023 | |
| Sobi, INC | $50.76 | 2022-2023 | |
| Adc Therapeutics America, INC. | $50.08 | 2022-2023 | |
| Emd Serono, INC. | $37.30 | 2024 | |
| Syndax Pharmaceuticals, INC. | $31.70 | 2025 | |
| Beone Medicines USA, INC. | $28.95 | 2025 | Brukinsa |
| Geron Corporation | $25.83 | 2025 | Rytelo |
| Blueprint Medicines Corporation | $24.72 | 2023 | Ayvakit |
| Servier Pharmaceuticals LLC | $24.27 | 2025 | |
| Azurity Pharmaceuticals, INC. | $21.90 | 2024 | Vivimusta |
| Iovance Biotherapeutics, INC. | $21.55 | 2024 | Amtagvi |
| Immunogen, INC. | $20.20 | 2023 | Elahere |
| Dova Pharmaceuticals | $19.41 | 2021 | |
| Pharmacosmos Therapeutics INC. | $18.04 | 2023 | Monoferric |
| Tersera Therapeutics LLC | $17.42 | 2021 | |
| Coherus Oncology, INC. | $15.16 | 2023 | |
| Morphosys, US INC. | $14.20 | 2023 | Monjuvi |
| Taiho Oncology, INC. | $12.07 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $11.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Krzus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.